Reinartz, Mariska http://orcid.org/0000-0001-7964-7963
Luckett, Emma Susanne http://orcid.org/0000-0003-1777-4742
Schaeverbeke, Jolien
De Meyer, Steffi
Adamczuk, Katarzyna
Thal, Dietmar Rudolf
Van Laere, Koen
Dupont, Patrick http://orcid.org/0000-0003-1980-2540
Vandenberghe, Rik http://orcid.org/0000-0001-6237-2502
Funding for this research was provided by:
Foundation for Alzheimer Research SAO-FRMA (09013, 11020, 13007)
Research Foundation Flanders (G094418N, G0F8516N, G0G1519N)
KU Leuven (C14/17/108, C14/21/109)
Vlaams Agentschap voor Innovatie en Onderzoek (HBC.2019.2523)
Article History
Received: 20 December 2021
Accepted: 19 April 2022
First Online: 6 May 2022
Declarations
:
: The F-PACK cohort study has been approved by the UZ/KU Leuven Ethics Committee for Clinical studies (study number S51125). The <sup>18</sup>F-flutemetamol end-of-life study was approved by the Institutional Review Boards or Ethics Committees at the following institutions which approved the study protocol before initiation: Compass Research, Galiz Research, LasVegas Radiology, Premier Research Institute, Banner Sun Health Research Institute, Mt Sinai Medical Center,Wien Center for Alzheimer’s Disease,Warren Alpert Medical School of Brown University, Banner Alzheimer’s Institute, University of Michigan, Moorgreen Hospital, VERITAS Research, St Margaret’s Hospital, Miami Jewish Health Systems, Memory Enhancement Center, Oxford Radcliffe Hospitals, Michigan State University, Exodon LLC, and Barrows Neurological Institute.
: Written informed consent was obtained from all individual participants included in the F-PACK study. Written informed consent was obtained from all individual participants or their legal representatives for the <sup>18</sup>F-flutemetamol end-of-life study.
: DRT received honoraria as consultant for assessing amyloid pathology for the GE-067–026 trial from GE-HC and Convance. He also received speaker honoraria from Novartis Pharma Basel (Switzerland) and Biogen (USA); travel reimbursement from GE-Healthcare (UK), and UCB (Belgium); and collaborated with GE-Healthcare (UK), Novartis Pharma Basel (Switzerland), Probiodrug (Germany), and Janssen Pharmaceutical Companies (Belgium). JS is a junior postdoctoral fellow of the FWO (12Y1620N). KA is a full time employee of Bioclinica, Newark, CA, USA. KVL has received speaker fees by GE-HC. RV has received research grants from Research Foundation—Flanders (FWO) and KU Leuven, has had a clinical trial agreement for phase 1 and 2 study between University Hospitals Leuven and GE-HC, has received a non-financial support from GE-HC (provision of <sup>18</sup>F-Flutemetamol for conduct of investigator-driven trial free of cost), and has a clinical trial agreement (local principal investigator) between University Hospitals Leuven and Biogen, J&J, NovoNordisk, Roche, and UCB. All other authors declare no competing interests.